Clinical trial
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary…
NCT00028743 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00028743 |
|---|---|
| Title | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| Official title | A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | European Organisation for Research and Treatment of Cancer - EORTC Grupo Español de Investigación en Cáncer de Ovario |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cisplatin, paclitaxel, topotecan hydrochloride |
| Enrollment | 819 |
| Start date | Aug 31, 2001 |
| Primary completion | Mar 5, 2008 |
| Completion | Jan 10, 2013 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 2, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: